Predictors of medication nonadherence among patients with diabetes in Medicare Part D programs: A retrospective cohort study

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2178-2188

  Yang, Yi ^a   Thumula, Vennela ^a   Pace, Patrick F ^a   Banahan III, Benjamin F ^a   Wilkin, Noel E ^a   Lobb, William B ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

ACEI ARB; diabetes; Medicare Part D; medication nonadherence; oral hypoglycemic agent; statin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ORAL ANTIDIABETIC AGENT;

AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; ETHNIC DIFFERENCE; FEMALE; HEALTH PROGRAM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREDICTION; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; ETHNIC GROUPS; FEMALE; FLORIDA; FORECASTING; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MEDICARE PART D; MIDDLE AGED; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES;

EID: 71549115759     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.10.002     Document Type: Article

References (50)

1. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
2. National Diabetes Information Clearinghouse, National Institute of Diabetes and Digestive and Kidney Diseases, and National Institutes of Health. National Diabetes Statistics (2007). http://diabetes.niddk.nih.gov/DM/PUBS/statistics Accessed September 14, 2009
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) [published correction appears in Lancet. 1998;352:1558]. Lancet 352 (1998) 854-865
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339 (1998) 1349-1357
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
6. Adler A.I., Stratton I.M., Neil H.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 321 (2000) 412-419
7. Rodbard H.W., Blonde L., Braithwaite S.S., et al., AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus [published correction appears in Endocr Pract. 2008;14:802-803]. Endocr Pract 13 Suppl 1 (2007) 1-68
8. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 31 Suppl 1 (2008) S12-S54
9. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
10. Collins R., Armitage J., Parish S., et al., Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebocontrolled trial. Lancet 361 (2003) 2005-2016
11. Hansson L., Zanchetti A., Carruthers S.G., et al., HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
12. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 335 (1996) 1001-1009
13. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321 (2000) 405-412
14. American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care 30 Suppl 1 (2007) S4-S41
15. Cramer J.A. A systematic review of adherence with medications for diabetes. Diabetes Care 27 (2004) 1218-1224
16. Rosen A.B., Karter A.J., Liu J.Y., et al. Use of angiotensinconverting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes. J Gen Intern Med. 19 (2004) 669-675
17. Lerman I. Adherence to treatment: The key for avoiding long-term complications of diabetes. Arch Med Res. 36 (2005) 300-306
18. Rubin R.R. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 118 Suppl 5A (2005) 27S-34S
19. Ho P.M., Rumsfeld J.S., Masoudi F.A., et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 166 (2006) 1836-1841
20. Personal determinants. In: Gochman D.S. (Ed). Handbook of Health Behavior Research (1997), Plenum Press, New York, NY 41-51
21. Hertz R.P., Unger A.N., and Lustik M.B. Adherence with pharmacotherapy for type 2 diabetes: A retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther. 27 (2005) 1064-1073
22. Rozenfeld Y., Hunt J.S., Plauschinat C., and Wong K.S. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 14 (2008) 71-75
23. Benner J.S., Glynn R.J., Mogun H., et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 288 (2002) 455-461
24. Lummis H.L., Sketris I.S., Gubitz G.J., et al. Medication persistence rates and factors associated with persistence in patients following stroke: A cohort study. BMC Neurol. 8 (2008) 25
25. Tjia J., and Schwartz J.S. Will the Medicare prescription drug benefit eliminate cost barriers for older adults with diabetes mellitus?. J Am Geriatr Soc. 54 (2006) 606-612
26. Yin W., Basu A., Zhang J.X., et al. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 148 (2008) 169-177
27. US Dept of Health & Human Services (HHS). Nearly 24 million Medicare beneficiaries now have prescription drug coverage. http://www.hhs.gov/news/press/2006pres/20060117.html Accessed September 9, 2008
28. Neuman P., Strollo M.K., Guterman S., et al. Medicare prescription drug benefit progress report: Findings from a 2006 national survey of seniors. Health Aff (Millwood) 26 (2007) w630-w643
29. US Dept of Health & Human Services. Health information privacy. http://www.hhs.gov/ocr/privacy/ Accessed September 14, 2009
30. Centers for Disease Control and Prevention, National Center for Health Statistics. Classification of diseases, functioning, and disability. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). http://www.cdc.gov/nchs/icd/icd9cm.htm Accessed September 29, 2009
31. Benner J.S., Pollack M.F., Smith T.W., et al. Association between shortterm effectiveness of statins and longterm adherence to lipid-lowering therapy. Am J Health Syst Pharm. 62 (2005) 1468-1475
32. Chapman R.H., Benner J.S., Petrilla A.A., et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 165 (2005) 1147-1152
33. Ho P.M., Magid D.J., Shetterly S.M., et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 155 (2008) 772-779
34. Mauskopf J.A., Paramore C., Lee W.C., and Snyder E.H. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm. 11 (2005) 231-251
35. Peterson A.M., Nau D.P., Cramer J.A., et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 10 (2007) 3-12
36. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 40 (1987) 373-383
37. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
38. Erkens J.A., Klungel O.H., Stolk R.P., et al. Cardiovascular drug use and hospitalizations attributable to type 2 diabetes. Diabetes Care 24 (2001) 1428-1432
39. Sirois C., Moisan J., Poirier P., and Gregoire J.P. Suboptimal use of cardioprotective drugs in newly treated elderly individuals with type 2 diabetes. Diabetes Care 30 (2007) 1880-1882
40. Yurgin N., Secnik K., and Lage M.J. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: A retrospective database study. Clin Ther 29 (2007) 316-325
41. Johnson M.L., and Singh H. Patterns of antihypertensive therapy among pa- tients with diabetes. J Gen Intern Med. 20 (2005) 842-846
42. Lau D.T., and Nau D.P. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 27 (2004) 2149-2153
43. Fitz-Simon N., Bennett K., and Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag 1 (2005) 93-106
44. Cooke C.E., and Fatodu H. Physician conformity and patient adherence to ACE inhibitors and ARBs in patients with diabetes, with and without renal disease and hypertension, in a Medicaid managed care organization. J Manag Care Pharm. 12 (2006) 649-655
45. Balkrishnan R., Rajagopalan R., Camacho F.T., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 25 (2003) 2958-2971
46. Sokol M.C., McGuigan K.A., Verbrugge R.R., and Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 43 (2005) 521-530
47. Lawrence D.B., Ragucci K.R., Long L.B., et al. Relationship of oral antihy-perglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm. 12 (2006) 466-471
48. Pladevall M., Williams L.K., Potts L.A., et al. Clinical outcomes and adherence to medications measured by claims data in patients with diabetes. Diabetes Care 27 (2004) 2800-2805
49. Stolar M.W., Hoogwerf B.J., Gorshow S.M., et al. Managing type 2 diabetes: Going beyond glycemic control. J Manag Care Pharm. 14 Suppl B (2008) s2-s19
50. Steiner J.F., and Prochazka A.V. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol. 50 (1997) 105-116